AstraZeneca: remarkable results in breast cancer
(CercleFinance.com) - At the weekend AstraZeneca announced that updated results from a Phase Ib/II trial showed that the combination of datopotamab deruxtecan (Dato-DXd) and Imfinzi (durvalumab) delivered durable tumor responses and no new safety signals in patients with untreated advanced or metastatic triple-negative breast cancer (TNBC).
Around 300,000 people worldwide are diagnosed with TNBC, the most aggressive subtype of breast cancer, every year.
The results obtained are described as "very encouraging", with a response rate of 79%. The magnitude of the response is particularly remarkable given that the majority of patients in this cohort have weak PD-L1 tumors, representing a population for whom treatment has long been limited to standard chemotherapy, an investigator in the trial said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Around 300,000 people worldwide are diagnosed with TNBC, the most aggressive subtype of breast cancer, every year.
The results obtained are described as "very encouraging", with a response rate of 79%. The magnitude of the response is particularly remarkable given that the majority of patients in this cohort have weak PD-L1 tumors, representing a population for whom treatment has long been limited to standard chemotherapy, an investigator in the trial said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.